Clinical Pharmacology Consulting
The Aclairo clinical pharmacology team has decades of experience in providing guidance, analysis, and reporting in support of development of a vast array of therapeutics and indications globally.
Clinical Pharmacology Overview
Aclairo clinical pharmacology consultants advance a client’s drug development activities via integrating pharmacokinetic, pharmacodynamic, dose selection, exposure response, drug interaction, and special population assessments to guide safe and effective use of a drug in patients with a clear rationale that will be acceptable to regulators. The Aclairo Team has extensive experience in the conception, execution, and composition of regulatory submissions (pIND, IND, NDA, CTD, BLA, 510k, etc.), covering a wide array of delivery systems, routes of administration, therapeutics, and novel indications.
When is Clinical Pharmacology Consulting Needed?
- Candidate selection process
- Early-stage proof of concept/feasibility studies
- Study development and protocol design
- Dose selection, optimization, and regimen justification
- Biomarker/Bioanalytical strategy and assay interpretation
- Nonclinical to Clinical Translational Justification
- Registration dossier development and support in preparation for regulatory interactions
Expertise in Clinical Pharmacology
- Design and implementation of tailored clinical pharmacology program strategies
- Integration into client project teams
- Formulation and implementation of clinical pharmacology program approaches for global regulatory submissions (US, EU, AU, Japan, China, and others)
- Design, evaluation and implementation of bioanalytical methodologies
- Correlation of exposure to activity and biomarkers
Our Clinical Pharmacology Process
Aclairo clinical pharmacology consultants tailor each program to the client’s development stage, therapeutic modality, route of administration, target population, and regulatory objectives. Our process integrates nonclinical findings, clinical data, pharmacokinetics, pharmacodynamics, exposure response, and regulatory strategy to support dose selection, study progression, and submission planning.
Program Assessment and Strategy Development
Aclairo reviews relevant information to identify key development questions and program gaps. This assessment is used to develop a clinical pharmacology strategy that supports first-in-human planning, dose escalation, dose optimization, special population considerations, drug interaction assessment, and regulatory expectations.
Study Design and Protocol Development
Aclairo supports the design of fit-for-purpose clinical pharmacology studies, developed to generate interpretable data that support safety, efficacy, dose justification, and future regulatory submissions.
Execution Support and Oversight
Aclairo provides scientific oversight during study conduct, including support for sampling schedules, bioanalytical and biomarker planning, data review, protocol interpretation, and emerging issue resolution. This helps ensure that clinical pharmacology studies are conducted in a manner that produces reliable and decision-ready data.
Data Analysis, Modeling, and Interpretation
Aclairo analyzes and interprets PK, PD, biomarker, safety, and efficacy data to characterize drug exposure and clinical outcomes using various PK/PD modeling, population PK modeling, PBPK modeling, NCA, compartmental modeling, and simulation approaches to support dose selection, regimen optimization, and development decisions.
Reporting and Regulatory Submission Support
Aclairo prepares and reviews clinical pharmacology reports, integrated summaries, regulatory briefing materials, labeling language, and CTD submission sections. These materials support IND, NDA, BLA, CTA, and other global regulatory submissions by clearly explaining the clinical pharmacology rationale for dosing, safety, efficacy, special population use, and benefit–risk assessment.
Related Services
Frequently Asked Questions
- What is the role of clinical pharmacology in drug development? Clinical pharmacology defines how a drug is absorbed, distributed, metabolized, and eliminated in humans and patients. It supports dose selection, safety assessment, drug interaction evaluation, and use in special populations.
- When is PK/PD modeling required? PK/PD modeling links drug exposure to efficacy, safety, or biomarkers. It supports dose selection and regimen justification. It is especially useful for bridging across species, patient populations, or studies.
- What is the difference between PK and PD? Pharmacokinetics (PK) characterizes the behavior of a drug in the body while pharmacodynamics (PD) relates these changes to the drug’s activity.
- How does clinical pharmacology support regulatory submissions? Clinical pharmacology characterizes how a therapeutic dose or plasma concentration affects exposure, efficacy, and safety. It provides key evidence for dose selection, drug interaction risk, food effects, organ impairment, and special populations. These data help justify labeling recommendations and support the overall benefit/risk assessment.
- What is involved in first-in-human (FIH) study design? First-in-human study design involves selecting a safe starting dose, dose-escalation plan, dosing schedule, and safety monitoring strategy based on nonclinical pharmacology and toxicology data. The goal is to evaluate initial human safety while generating data to guide further clinical development.